Treatment Preferences in Adults With Chronic Spontaneous Urticaria Symptomatic on H1-Antihistamines in China: Insights From CHOICE-CSU 2 Study

Author(s)

Qiquan Chen, Doctor1, Cristina Constantinescu, doctor2, XIAOXIAO REN, Master3, Wanjie Guo, Master3, panagiotis Orfanos, II, BSc, MPhil, MSc4, Ravneet Kaur Kohli, Other5, Zhiqiang Song, Doctor1.
1The Southwest hospital of AMU, Chongqing, China, 2Ipsos, Basel, Switzerland, 3Novartis Pharma Co., Ltd., Beijing, China, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Healthcare Pvt. Ltd., Hyderabad, India.
OBJECTIVES: Chronic spontaneous urticaria (CSU) is characterized by unpredictable itch, and hives with or without angioedema lasting over six weeks without external triggers. With the development of novel therapies, understanding patient preferences for treatment attributes, such as efficacy, safety, and mode of administration, is critical. The CHOICE-CSU 2 study evaluated treatment preferences among adult patients with CSU inadequately controlled by H1- antihistamines in China.
METHODS: A quantitative online survey was conducted among adult patients with CSU in China, who were inadequately controlled by H1-antihistamines (Urticaria Control Test 7 [UCT] < 12). The relative importance of treatment attributes and preference between hypothetical treatment profiles were identified using a Maximum Different Scaling Exercise and a Discrete Choice Experiment. Key attributes assessed included urticaria control, speed of onset of treatment effect, impact on quality of life (QoL), sleep improvement, swelling reduction, mode of administration, side effects, and injection site reactions. Sensitivity analysis with scenarios of parity in efficacy were conducted to assess robustness of the results.
RESULTS: The analysis included 150 patients with CSU (61% women, median age 37 years). The overall UCT median score was 8.0. Based on patient preferences, the top five prioritized attributes were side effects (96.8%), the impact on QoL (91.6%), fast treatment effect (88.5%), well-controlled urticaria (72.3%), and improvement in sleep problems (66.2%). When attributes were evaluated using comparable clinical trial data, 75.1% of patients preferred oral treatment over injectable. Scenarios assuming parity in efficacy consistently indicated a stronger preference for oral treatments.
CONCLUSIONS: Patients prefer oral CSU treatments over injectables when efficacy and safety are comparable. The most important attributes patients consider when choosing a therapy are side effects, the impact on QoL and fast treatment effect.

Conference/Value in Health Info

2025-11, ISPOR Europe 2025, Glasgow, Scotland

Value in Health, Volume 28, Issue S2

Code

PCR250

Topic

Patient-Centered Research

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Sensory System Disorders (Ear, Eye, Dental, Skin)

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×